<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1499">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141643</url>
  </required_header>
  <id_info>
    <org_study_id>21-442</org_study_id>
    <nct_id>NCT05141643</nct_id>
  </id_info>
  <brief_title>Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer</brief_title>
  <official_title>18F-FAC PET Imaging to Quantify Gemcitabine Tumor Drug Uptake and Biodistribution in Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Before participants begin to receive the standard treatment for their cancer they will&#xD;
      receive an intravenous (IV) injection of 18F-FAC and perform a PET scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2021</start_date>
  <completion_date type="Anticipated">November 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 18, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor drug uptake within PDAC tumors prior at pre-treatment baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The primary objective of this study is to obtain preliminary data of tumor drug uptake profile, concentration and distribution within PDAC tumors prior at pre-treatment baseline</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Participants with pancreatic ductal adenocarcinoma (PDAC)</arm_group_label>
    <description>Participants will have histologically-confirmed pancreatic ductal adenocarcinoma (PDAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET Scan</intervention_name>
    <description>Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of [18F]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging).</description>
    <arm_group_label>Participants with pancreatic ductal adenocarcinoma (PDAC)</arm_group_label>
    <other_name>18F-FAC PET Scan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential patients will be identified by a member of the patient's treatment team at MSKCC&#xD;
        and will be referred to the Investigator/Consenting Professional in Molecular Imaging and&#xD;
        Therapy Service (MITS). The Investigator/Consenting Professional from MITS will discuss the&#xD;
        study in detail with the potential patient, answer questions, and give ample time for&#xD;
        consideration of the study. Written informed consent will be obtained and also documented&#xD;
        by the Consenting Professional in the medical record. Alternatives, including not enrolling&#xD;
        in this protocol, will be discussed in detail with patient. After signing informed consent,&#xD;
        the patient will be registered through CTMS. Participation in this study will be entirely&#xD;
        voluntary.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically-confirmed (confirmed at MSKCC) PDAC&#xD;
&#xD;
          -  Patients must be ≥ 18 years old&#xD;
&#xD;
          -  Signed, written Institutional Review Board (IRB)-approved Informed Consent Form (ICF).&#xD;
&#xD;
          -  Measurable or evaluable solid disease on computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI) scan per RECIST v1.1.&#xD;
&#xD;
          -  Karnofsky Performance Status ≥70%.&#xD;
&#xD;
          -  Life expectancy ≥3 months.&#xD;
&#xD;
          -  A negative serum pregnancy test, within 1 week of the procedure, if the patient is&#xD;
             female of reproductive potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who cannot undergo PET/CT scanning (i.e. because of weight limits,&#xD;
             claustrophobia).&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heiko Schoder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heiko Schoder, MD</last_name>
    <phone>212-639-2079</phone>
    <email>schoderh@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Humm, PhD</last_name>
    <phone>212-639-7367</phone>
    <email>hummj@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heiko Schoder, MD</last_name>
      <phone>212-639-2079</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>pancreatic ductal adenocarcinoma</keyword>
  <keyword>18F-FAC</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>21-442</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

